Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2015

View Archived Issues

New models of neurological disorders using genetic manipulation described

Evotec collaborates with Beyond Batten Disease Foundation

Kite Pharma enters into license agreement with the NIH for TCR-based products

HighTide Biopharma starts phase I trial of antidiabetic candidate HTD-4010

Novel PSMA ligand shows promise as a theranostic for prostate cancer

Tofacitinib is beneficial in treating atopic dermatitis in phase IIa study

AFA-19 mitigates neuropathic pain and reduces PTZ-induced seizures in mice

NeoGenomics to acquire Clarient

UT Austin receives Gates Foundation grant to study hu1B7 as pertussis prophylaxis

Takeda initiates phase I study of TAK-831 in development for schizophrenia and cerebellar ataxia

CFFT awards grant to Southern Research to identify drugs for rare CF variants

KemPharm completes intranasal abuse liability trial of KP-201/acetaminophen

Zydus Research Centre presents new anticancer compounds

Model allows testing of fecal microbiota transplantation for Clostridium difficile infection

Glycolysis inhibitor WP-1122 has additional effects on glioblastoma cells

Chugai Pharmaceutical profiles progress of third quarter 2015

Minomic signs agreement enabling clinical trial of cancer imaging agent

Bayer Schering Pharma patents MMP-12 inhibitors

Huabo Biopharm describes new recombinant bifunctional fusion protein

Sanofi develops GDIR agonists

Lupin reports BTK inhibitors

Janssen Pharmaceutica discloses EEF2K and/or PIK3C3 inhibitors

Genvoya noninferior to Stribild in phase III studies in treatment-naive adults with HIV infection

FDA approves Merrimack's liposomal irinotecan for pancreatic cancer

Ocular Therapeutix reports trial results for OTX-TP and Dextenza

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...